The Oncology Service – Richmond
  • Phone: 804-999-0001
  • Our Services
    • Medical Oncology
    • Radiation Oncology
    • Stereotactic Radiation Therapy
    • Diagnostic Imaging
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Your First Visit
    • Client Portal
    • FAQ
    • Pet Insurance
    • Grief Resources
    • Clinical Studies
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • At a Glance
    • Ethos Materials for Clinics
    • Continuing Education
    • VetBloom CE
    • Clinical Studies
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Ethos Discovery
    • Contact Us
  • Blogs & Videos
    • Our Blogs
    • PAWEDcasts
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Veterinary Training Programs
The Oncology Service – Richmond
  • Our Services
    • Medical Oncology
    • Radiation Oncology
    • Stereotactic Radiation Therapy
    • Diagnostic Imaging
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Your First Visit
    • Client Portal
    • FAQ
    • Pet Insurance
    • Grief Resources
    • Clinical Studies
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • At a Glance
    • Ethos Materials for Clinics
    • Continuing Education
    • VetBloom CE
    • Clinical Studies
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Ethos Discovery
    • Contact Us
  • Blogs & Videos
    • Our Blogs
    • PAWEDcasts
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Veterinary Training Programs
  • Phone: 804-999-0001

Clinical Studies

  • Evaluating the Tolerability of Combination of Verdinexor and Doxorubicin in Dogs with Cancer

    Currently Enrolling

    Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

    Study Details
  • Trial Evaluating an Investigational Agent for Management of Transitional Cell Carcinoma

    Closed

    This trial is designed to evaluate the safety and preliminary pain management and anti-cancer effectiveness of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).

    Study Details
  • Dysbiosis Enhancing Linkage Towards Association with Canine Osteosarcoma (DEL-TACO Lite)

    Currently Enrolling

    Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.

    Study Details
The Oncology Service – Richmond
804-999-0001 | 5711 Staples Mill Road # 102 
  • Phone: 804-999-0001
  • Our Services
    • Medical Oncology
    • Radiation Oncology
    • Stereotactic Radiation Therapy
    • Diagnostic Imaging
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Your First Visit
    • Client Portal
    • FAQ
    • Pet Insurance
    • Grief Resources
    • Clinical Studies
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • At a Glance
    • Ethos Materials for Clinics
    • Continuing Education
    • VetBloom CE
    • Clinical Studies
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Ethos Discovery
    • Contact Us
  • Blogs & Videos
    • Our Blogs
    • PAWEDcasts
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Veterinary Training Programs
© 2022 The Oncology Service – Richmond
Website Design by Jackrabbit